Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents.
Int Rev Cell Mol Biol
; 330: 115-156, 2017.
Article
em En
| MEDLINE
| ID: mdl-28215530
ABSTRACT
Owing to their central role in the initiation and regulation of antitumor immunity, dendritic cells (DCs) have been widely tested for use in cancer immunotherapy. Despite several encouraging clinical applications, existing DC-based immunotherapy efforts have yielded inconsistent results. Recent work has identified strategies that may allow for more potent DC-based vaccines, such as the combination with antitumor agents that have the potential to synergistically enhance DC functions. Selected cytotoxic agents may stimulate DCs either by directly promoting their maturation or through the induction of immunogenic tumor cell death. Moreover, they may support DC-induced adaptive immune responses by disrupting tumor-induced immunosuppressive mechanisms via selective depletion or inhibition of regulatory subsets, such as myeloid-derived suppressor cells and/or regulatory T cells (Tregs). Here, we summarize our current knowledge on the capacity of anticancer chemotherapeutics to modulate DC phenotype and functions and the results of ongoing clinical trials evaluating the use of DC-based immunotherapy in combination with chemotherapy in cancer patients.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
2_ODS3
Base de dados:
MEDLINE
Assunto principal:
Células Dendríticas
/
Vacinação
/
Vacinas Anticâncer
/
Antineoplásicos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Int Rev Cell Mol Biol
Ano de publicação:
2017
Tipo de documento:
Article